FDA Approves Anti-Epileptic Drug XCOPRI

December 5, 2019

FDA Approves Anti-Epileptic Drug XCOPRI

The FDA granted approval to SK Biopharmaceuticals, Co., Ltd. and its U.S. subsidiary SK Life Science, Inc. for XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adult patients.This approval is the first time that a Korean pharmaceutical company has independently brought a compound from discovery to U.S. FDA approval. WIth our global footprint, Yourway is well positioned to support international clinical trials.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Longwood Healthcare Leaders

October 27-28, 2025
Mandarin Oriental Hotel, Boston

Schedule a Meeting

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?